Trump Drug Pricing Deals Expand As Johnson & Johnson Joins TrumpRx Platform
Johnson & Johnson will begin marketing four prescription drugs, including the diabetes drug metformin, on the Trump administration's TrumpRx website starting Friday, expanding low-cost options for uninsured patients. (Johnson & Johnson)
The agreement is voluntary and gives Medicaid access and marketing on TrumpRx in exchange for an exemption from the administration's tariff agenda, the company said. (exemption from the administration's tariff agenda) The move more than doubles the number of medications featured on the low-cost site. It applies only to patients who are uninsured or whose insurance does not cover the drug and who pay full list price.
The episode traces back to the president's push to tie U.S. drug prices to lower foreign rates and a May 2025 executive order to enforce most-favored-nation pricing. The administration launched TrumpRx on February 5, 2026 and paired pricing deals with 100% tariffs on imported patented drugs announced in April 2026 to push more companies into agreements. Earlier deals with companies like Pfizer, AstraZeneca and Regeneron set the pattern by trading lower U.S. prices and Medicaid access for tariff relief (Regeneron pricing deal).
The change could reach millions: about 27 million Americans lack health insurance and are the primary group eligible for TrumpRx discounts. Supporters hailed the growing drug list as rapid progress, while critics pointed to big pharmaceutical profits and the gap between U.S. prices and prices abroad. The inclusion of metformin targets a large patient base given roughly 14.7% of the U.S. population has diabetes.
Show source details & analysis (2 sources)
đ Relevant Data
TrumpRx, launched on February 5, 2026, initially featured approximately 43 discounted brand-name drugs, expanding to 54 by March 2026, providing coupons for most-favored-nation pricing to uninsured or cash-paying patients. ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx)) ([Wikipedia](https://en.wikipedia.org/wiki/TrumpRx))
TrumpRx - Wikipedia â Wikipedia
On April 2, 2026, President Trump imposed tariffs on imported patented pharmaceutical products to bolster national security and strengthen U.S. supply chains, from which Johnson & Johnson received an exemption as part of the deal. ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products)) ([The White House](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products))
Fact Sheet: President Donald J. Trump Bolsters National Security and Strengthens U.S. Supply Chains by Imposing Tariffs on Patented Pharmaceutical Products â The White House
As of 2026, approximately 27 million Americans lack health insurance, representing the primary group eligible for TrumpRx discounts. ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage)) ([MoneyGeek](https://www.moneygeek.com/insurance/health/americans-without-coverage))
Uninsured Americans 2026: 27M Without Coverage, ACA Subsidy Challenges â MoneyGeek
In 2026, approximately 14.7% of the U.S. population has diabetes, with about 1.2 million new cases diagnosed each year, predominantly Type 2 diabetes treatable with medications like metformin. ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics)) ([SingleCare](https://www.singlecare.com/blog/news/diabetes-statistics))
Diabetes statistics 2026 â SingleCare
đ Key Facts
- Johnson & Johnson will begin marketing four prescription medications on the Trump administration's TrumpRx website starting Friday (Johnson & Johnson).
- One of the initial J&J drugs added to the platform will be metformin, a common Type 2 diabetes medication (metformin).
- The J&J arrangement is structured as a voluntary agreement to lower costs by providing Medicaid access to affordable prescriptions and marketing on TrumpRx in exchange for an exemption from the president's tariff agenda (voluntary agreement).
- The addition of J&J drugs more than doubles the number of medications featured on the TrumpRx low-cost site, and the program is limited to patients who are uninsured or whose insurance does not cover the drug and who pay full list price (TrumpRx low-cost site).
- As part of its broader engagement with the administration, Johnson & Johnson previously agreed to invest $55 billion in research and production facilities in Pennsylvania and North Carolina (invest $55 billion).
đ° Source Timeline (2)
Follow how coverage of this story developed over time
- Johnson & Johnson will begin marketing four medications on the Trump administration's TrumpRx website starting Friday.
- The J&J deal is structured as a voluntary agreement to lower costs by providing Medicaid access to affordable prescriptions and marketing on TrumpRx in exchange for exemption from the president's tariff agenda.
- One of the initial J&J drugs on TrumpRx will be metformin, a common Type 2 diabetes prescription.
- The addition of J&J drugs more than doubles the number of medications featured on the TrumpRx low-cost site and is limited to patients who are uninsured or whose insurance does not cover the drug and who pay full list price.
- Johnson & Johnson previously agreed to invest $55 billion in research and production facilities in Pennsylvania and North Carolina as part of its broader engagement with the administration.